OLMA - Olema Pharmaceuticals, Inc.
IEX Last Trade
6.305
-0.025 -0.397%
Share volume: 11,241
Last Updated: Thu 26 Dec 2024 08:29:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$6.33
-0.03
-0.39%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.32%
1 Month
-34.98%
3 Months
-48.28%
6 Months
-42.86%
1 Year
-56.71%
2 Year
145.91%
Key data
Stock price
$6.30
DAY RANGE
$6.19 - $6.36
52 WEEK RANGE
$6.00 - $16.78
52 WEEK CHANGE
-$56.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Sean Bohen
Region: US
Website: olema.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: olema.com
Employees: 70
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Olema Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies for women's cancers. OP-1250, an estrogen receptor antagonist and a selective ER degrader, is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
Recent news